Compare BDSX & CDXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BDSX | CDXS |
|---|---|---|
| Founded | 2005 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precision Instruments | Major Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 122.0M | 141.8M |
| IPO Year | 2020 | 2008 |
| Metric | BDSX | CDXS |
|---|---|---|
| Price | $14.29 | $1.57 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $32.50 | N/A |
| AVG Volume (30 Days) | 129.7K | ★ 3.5M |
| Earning Date | 05-12-2026 | 03-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 43.82 |
| EPS | N/A | ★ N/A |
| Revenue | $88,499,000.00 | ★ $138,590,000.00 |
| Revenue This Year | $25.26 | $6.35 |
| Revenue Next Year | $19.70 | $16.62 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 24.08 | ★ 32.30 |
| 52 Week Low | $0.25 | $0.96 |
| 52 Week High | $20.21 | $3.87 |
| Indicator | BDSX | CDXS |
|---|---|---|
| Relative Strength Index (RSI) | 44.63 | 56.64 |
| Support Level | $6.33 | $1.57 |
| Resistance Level | $20.21 | $1.86 |
| Average True Range (ATR) | 1.47 | 0.19 |
| MACD | -0.59 | 0.03 |
| Stochastic Oscillator | 8.80 | 42.60 |
Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Covid tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.
Codexis Inc is a provider of enzymatic solutions for efficient and scalable therapeutics manufacturing that leverages its proprietary CodeEvolver technology platform to discover, develop, and enhance novel, high-performance enzymes. Codexis enzymes solve challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis' enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. Geographically, it derives maximum revenue from the Americas.